Antimicrobial Peptide WK-13-3D Provides Complete Protection Against Japanese Encephalitis Virus in Mice

A synthetic antimicrobial peptide achieved 100% survival in JEV-infected mice by directly binding and neutralizing viral particles before cell entry — a proof-of-concept that could open new post-exposure prophylaxis strategies for a disease with no approved antiviral treatment.

Japanese encephalitis virus (JEV) causes approximately 68,000 clinical cases annually, with a 20–30% case fatality rate and permanent neurological damage in up to 50% of survivors. Despite this burden, no antiviral drugs are currently approved for JEV treatment. Antimicrobial peptides (AMPs) — short, naturally occurring defense molecules — have shown broad-spectrum activity against bacteria, fungi, and some viruses, making them attractive candidates for antiviral development.

Key Findings

Chai et al. at the Chinese Academy of Agricultural Sciences (Lanzhou University) tested WK-13-3D, a synthetic analogue of the human cathelicidin LL-37, against JEV in cell culture and mouse models, published in Antiviral Research.¹

In vitro results:

• WK-13-3D significantly reduced JEV infection in human glioblastoma (T98G) cells
• The peptide was most effective when applied as pre-treatment or co-incubation during viral adsorption, suggesting it acts at the entry stage
• Mechanistic studies showed WK-13-3D binds directly to the JEV envelope (E) protein, preventing viral internalization

In vivo results:

• Pre-treating JEV with WK-13-3D before inoculation in mice provided 100% protection against mortality
• Control group survival was only 16.7% (1 of 6 mice)
• The peptide conferred protection specifically through direct viral neutralization rather than host immune modulation

Mechanism of Action

WK-13-3D appears to function as a viral entry inhibitor. By binding to the JEV envelope protein — the key mediator of host cell attachment and membrane fusion — the peptide physically blocks the virus from entering cells. This mechanism is distinct from traditional antivirals that target viral replication machinery and could theoretically be effective regardless of viral resistance mutations in polymerase genes.

Context and Limitations

This is a preclinical study with several important caveats. The mouse model used pre-treatment (mixing peptide with virus before injection), which represents an idealized prophylactic scenario rather than treating established infection. Whether WK-13-3D can cross the blood-brain barrier to reach JEV in the central nervous system — where the virus causes its most devastating damage — remains untested. Peptide stability, manufacturing scale-up, and potential immunogenicity would all need to be addressed before clinical development.

The study originates from a leading Chinese veterinary research institute, reflecting JEV's significance as both a human and animal health concern across Asia, where the virus is endemic in regions spanning from Japan to India.

Clinical implication: No immediate practice change, but this work validates antimicrobial peptides as a viable antiviral platform for JEV and potentially other flaviviruses. Clinicians in JEV-endemic regions should watch for clinical translation of peptide-based entry inhibitors as a complement to vaccination strategies.

---

¹ Chai F, Kassegn TA, Du J, et al. Antimicrobial Peptide WK-13-3D Inhibits Japanese Encephalitis Virus Infection by Interacting with Viral Particles, Potentially Targeting the Envelope Protein. Antiviral Res. 2026. doi:10.1016/j.antiviral.2026.106401